Valion Bio, Inc. entered into a letter agreement with 3i, LP to issue 50 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 1,539 common shares at $2.5520 per share for an aggregate price of $50,000. The transaction was conducted under a private placement exemption. Valion Bio operates in the biotechnology sector.
